Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "rituximab" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    Interstitial pneumonia during treatment with rituximab
    Autorzy:
    Leś, Dominika
    Polakiewicz-Gilowska, Anna
    Kaleta, Beata
    Starzyczny-Słota, Danuta
    Nowara, Elżbieta
    Powiązania:
    https://bibliotekanauki.pl/articles/1065045.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    complications
    interstitial pneumonia
    rituximab
    Opis:
    Rituximab (RTX) is a chimeric anti-CD20 antibody. It plays an important role in the treatment of B-cell lymphomas and diseases of autoaggression. RTX-induced lung disease is a rare entity, which should be considered in those patients treated with RTX who present with pulmonary disorders with no clear evidence of infection. A 37-year-old woman suffering from CD20-positive DLBCL (diffuse large B-cell lymphoma) received two cycles of the R-CHOP (RTX, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen. After the second cycle of immunochemotherapy, symptoms of interstitial pneumonia occurred. Having excluded all the other causes, it was diagnosed as a complication associated with the administration of RTX.
    Źródło:
    OncoReview; 2015, 5, 1; A16-A20
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cardiac complications during DLBCL treatment using R-CHOP
    Autorzy:
    Sosnowska-Pasiarska, Barbara
    Zgódka, Paweł
    Steckiewicz, Paulina
    Pasiarski, Marcin
    Powiązania:
    https://bibliotekanauki.pl/articles/1035760.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    DLBCL
    implantable cardioverter-defibrillator
    rituximab
    sudden cardiac arrest
    Opis:
    Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.
    Źródło:
    OncoReview; 2019, 9, 1; 22-26
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Quality of life patients treated with rituximab intravenous vs. subcutaneous in B-cell lymphomas: results from outpatient Hematooncology Clinic in Lodz
    Autorzy:
    Witkowska, Magdalena
    Witkowska, Sonia
    Klimczak, Marika
    Frydecka, Anna
    Witkowski, Michał
    Smolewski, Piotr
    Powiązania:
    https://bibliotekanauki.pl/articles/2047211.pdf
    Data publikacji:
    2021-07-14
    Wydawca:
    Medical Education
    Tematy:
    Rituximab
    quality of life
    anti CD20
    B-cell NHL
    lymphoma
    Opis:
    Introduction: Nowadays, rituximab is available both as intravenous (IV) and subcutaneous (SC) formulations. The aim of this study is to compare quality of life (QOL) of patients treated in Hematooncology Clinic in Lodz with B-cell nonHodgkin lymphoma (B-NHL) treated with rituximab IV and SC. Material and Methods: In 50 adult patients with B-NHL diagnosis we assessed QOL by three different questionnaries (EORTC QLQ-C30, FACT/ GOG-NTx and EQ-5D). We compared it between patients treated with rituximab IV and SC. Results: In comparison of general condition in EQ-5D-3L and EORTC QLQ-C30 questionnaire patients treated with rituximab SC felt statistically better than with IV administration (p<0.01). In SC group general health was evaluated for 72 while in IV for only 58,1. According to FACT/GOG-NTx questionnaire SC group had significantly better physical well-being. In SC group we observed statistically more complete responses (CR) 21 (88%) versus 17 (65%) in IV group. Moreover, trend was observed in emotional well-being in favor of SC treatment. Discussion: In our study we observed for the first time in the literature statistical difference in frequency of vomiting, nausea, and lack of appetite mentioned from our patients in questionnarie. It is very important that this findings were not published in any other study comparing SC and IV route od administration. Also looking at economic side of SC administration, this type of dosing. As a result it should be preferred form for B-cell lymphoma patients.
    Źródło:
    OncoReview; 2021, 11, 2; 33-39
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies